A multicenter study of the clinicopathological characteristics and a risk prediction model of early-stage breast cancer with hormone receptor-positive/human epidermal growth factor receptor 2-low expression.
10.1097/CM9.0000000000002831
- Author:
Ling XIN
1
;
Qian WU
1
;
Chongming ZHAN
2
;
Hongyan QIN
2
;
Hongyu XIANG
1
;
Min GAO
1
;
Xuening DUAN
1
;
Yinhua LIU
1
;
Jingming YE
1
Author Information
1. Department of Breast and Thyroid, Peking University First Hospital, Beijing 100034, China.
2. Jun Yi Tai He Medical Technology Co. Ltd., Beijing 100024, China.
- Collective Name:Chinese Society of Breast Surgery (CSBrS);Chinese Society of Surgery of Chinese Medical Association
- Publication Type:Journal Article
- MeSH:
Humans;
Female;
Breast Neoplasms/diagnosis*;
Ki-67 Antigen;
Receptor, ErbB-2;
Prognosis;
Thrombosis;
Receptors, Progesterone
- From:
Chinese Medical Journal
2023;136(24):2967-2973
- CountryChina
- Language:English
-
Abstract:
BACKGROUND:In light of the significant clinical benefits of antibody-drug conjugates in clinical trials, the human epidermal growth factor receptor 2 (HER2)-low category in breast cancers has gained increasing attention. Therefore, we studied the clinicopathological characteristics of Chinese patients with hormone receptor (HR)-positive/HER2-low early-stage breast cancer and developed a recurrence risk prediction model.
METHODS:Female patients with HR-positive/HER2-low early-stage breast cancer treated in 29 hospitals of the Chinese Society of Breast Surgery (CSBrS) from Jan 2015 to Dec 2016 were enrolled. Their clinicopathological data and prognostic information were collected, and machine learning methods were used to analyze the prognostic factors.
RESULTS:In total, 25,096 patients were diagnosed with breast cancer in 29 hospitals of CSBrS from Jan 2015 to Dec 2016, and clinicopathological data for 6486 patients with HER2-low early-stage breast cancer were collected. Among them, 5629 patients (86.79%) were HR-positive. The median follow-up time was 57 months (4, 76 months); the 5-year disease-free survival (DFS) rate was 92.7%, and the 5-year overall survival (OS) rate was 97.7%. In total, 412 cases (7.31%) of metastasis were observed, and 124 (2.20%) patients died. Multivariate Cox regression analysis revealed that T stage, N stage, lymphovascular thrombosis, Ki-67 index, and prognostic stage were associated with recurrence and metastasis ( P <0.05). A recurrence risk prediction model was established using the random forest method and exhibited a sensitivity of 81.1%, specificity of 71.7%, positive predictive value of 74.1%, and negative predictive value of 79.2%.
CONCLUSION:Most of patients with HER2-low early-stage breast cancer were HR-positive, and patients had favorable outcome; tumor N stage, lymphovascular thrombosis, Ki-67 index, and tumor prognostic stage were prognostic factors. The HR-positive/HER2-low early-stage breast cancer recurrence prediction model established based on the random forest method has a good reference value for predicting 5-year recurrence events.
REGISTRITATION:ChiCTR.org.cn, ChiCTR2100046766.
